All News

Early adoption of the MOLLI wireless localization system demonstrated a rapid learning curve, fewer missed biopsy clips, and a significant reduction in operating room delays compared with traditional needle localization.

In 161 biopsied breast masses, malignant lesions showed significantly higher E-strain ratios than benign lesions (3.51 vs 1.93), with progressive increases across BI-RADS categories, supporting elastography as an adjunct to biopsy decision-making.

Amer Zeidan, MBBS, MD, discussed when to start luspatercept at the full 1.75 mg/kg dose in lower-risk MDS based on the MAXILUS trial.

Patients with clinically higher-risk disease but favorable GPS results had higher 6-year EFS rates across treatment arms vs those at a lower clinical risk.

Nicholas Hornstein, MD, PhD, ranks RASolute 302, BREAKWATER, MATTERHORN, and more in a real-time discussion on Double Blind.

Experts discuss how to navigate coding, reimbursement, and other potential financial strains when treating patients via radiotherapy.

This literature review and institutional case report describes primary NECB with synchronous pancreatic and liver metastases as an extraordinarily rare, aggressive phenotype requiring multidisciplinary management driven by tumor biology rather than surgery.

Post-surgical pyoderma gangrenosum was successfully managed following bilateral mastectomy after clinical recognition prompted a shift to immunosuppressive therapy, avoiding further surgical debridement and achieving eventual wound healing.

At EHA, Benoit Tessoulin, MD, PhD, shared data showing the epcoritamab/R² combination benefitted all relapsed/refractory follicular lymphoma subgroups.

FDA breakthrough designation and NCCN inclusion elevate Merlin CP-GEP as a tool to refine SLNB decisions in T1b/T2a melanoma, per MERLIN_001 trial data.

Updated phase 2a data showed durable survival in a small subset of heavily pretreated patients with advanced pancreatic cancer treated with namodenoson.

Full phase 3 MANGROVE trial data will be presented at an upcoming medical meeting, with global regulatory submissions planned for the second half of 2026.

“[Epcoritamab/R2] is a good option for [patients] at first relapse or even further, even if they are very high risk,” said Benoit Tessoulin, MD, PhD.

In this retrospective cohort study, it was shown that acute pancreatitis hospitalizations occurred more frequently in patients with multiple myeloma who were older and more medically complex.

Experts discuss the evolving frontline CML treatment landscape, the impact of asciminib, and clinical strategies for achieving treatment-free remission.

The MagUS magnetically-guided ultrasound biopsy technique enabled successful sentinel lymph node biopsy de-escalation in 7 patients who preferred axillary evaluation to surgical staging, with all pathology returning negative.

Data from the phase 3 Precision-T trial support the FDA approval of allogeneic regulatory T-cell–based immunotherapy.

In 42 patients with DCIS undergoing breast-conserving surgery, 71.4% had detectable disseminated cancer cells in bone marrow, with residual-risk DCISionRT score significantly correlated with higher DCC burden compared with low- and elevated-risk groups.

In this patient case, a 72-year-old male with primary malignant melanoma of the ascending colon received adjuvant therapy consisting of immunotherapy with PD-1 inhibitors.

In this Satellite Session, experts convened to discuss CAR T-cell candidacy among patients across a range of large B-cell lymphoma disease states.

According to Chinmay Jani, MD, a current goal in thoracic oncology is to turn lung cancer into a “chronic disease” where patients can live for decades.

The safety profile of epcoritamab when added to lenalidomide was consistent with the known profiles of each individual agent among this DLBCL population.

Two teams of lung cancer experts face off to determine the optimal first-line treatment regimen in EGFR-mutated metastatic NSCLC.

This survey-based TIP study examines patient-perceived barriers to home recovery after mastectomy within a single ERAS-enabled hospital system, aiming to identify why patients decline same-day discharge despite being clinically eligible.

In 433 patients undergoing breast surgery, median VAS pain scores declined from 2 on day 1 to 0 by day 30, with severe pain in only 7.4% and opioid use in 2.5%, supporting nonopioid-based analgesic protocols.

ASCO Breakthrough 2026 spotlighted liquid biopsy, biomarkers, AI, and global equity, showing how data-driven precision oncology shapes personalized cancer care worldwide.

Teclistamab-based induction yielded a 100% overall response rate in transplant-eligible newly diagnosed multiple myeloma in the phase 2 MajesTEC-5 trial.

The FDA has accepted a BLA resubmission for RP1 plus nivolumab for patients with advanced melanoma.

Matthew Matasar, MD, discussed standout lymphoma readouts from ASCO and EHA 2026, including the frontMIND trial and emerging bispecific antibody regimens.

In 1153 women undergoing breast imaging and NCB, BIRADS 5 status, symptomatic presentation, and age over 70 years were associated with shorter time to biopsy, while socioeconomic and demographic factors were not significant predictors of delay.